New triple therapy offers hope for AML patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with AML according to the WHO (2022) or ICC criteria, or with MDS/AML as defined by ICC (with 10%-20% blasts in the bone marrow) * Age ≥ 14 years, male or female. * Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-2. * Meet the following laboratory requirements (tests must be performed within 7 days prior to treatment): i. Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) for the corresponding age group. ii. AST and ALT ≤ 2.5 times ULN for the corresponding age group. iii. Serum creatinine \< 1.5 times ULN for the corresponding age group. iv. Cardiac enzymes \< 2 times ULN for the corresponding age group. v. Left ventricular ejection fraction (LVEF) within the normal range as measured by echocardiography (ECHO). Exclusion Criteria: * Acute promyelocytic leukemia with PML::RARA fusion gene. * Acute myeloid leukemia with RUNX1::RUNX1T1 fusion gene. * Acute myeloid leukemia with BCR::ABL1 fusion gene. * Previously treated patients (defined as having received prior induction chemotherapy for AML/MDS; prior use of cytoreductive agents like hydroxyurea is allowed). * Concurrent active malignancy of other organs (requiring treatment). * Active cardiac disease, defined as one or more of the following: i. History of uncontrolled or symptomatic angina. ii. Myocardial infarction within 6 months prior to study enrollment. iii. History of clinically significant arrhythmia requiring medication or causing severe symptoms. iv. Uncontrolled or symptomatic congestive heart failure (\> New York Heart Association \[NYHA\] Class 2). * Active, uncontrolled infectious diseases (e.g., untreated tuberculosis, pulmonary aspergillosis). * Any other condition that, in the opinion of the investigator, makes the patient unsuitable for study participation.